Search hospitals

>

South Carolina

>

Charleston

Medical University of South Carolina

Claim this profile

Charleston, South Carolina 29401

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Breast Cancer

Conducts research for Stroke

Conducts research for Heart Failure

2284 reported clinical trials

177 medical researchers

Photo of Medical University of South Carolina in CharlestonPhoto of Medical University of South Carolina in CharlestonPhoto of Medical University of South Carolina in Charleston

Summary

Medical University of South Carolina is a medical facility located in Charleston, South Carolina. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Stroke, Heart Failure and other specialties. Medical University of South Carolina is involved with conducting 2,284 clinical trials across 2,109 conditions. There are 177 research doctors associated with this hospital, such as Jacqueline M. Kraveka, Gregory Cote, MD, Michael Gold, MD, and Mariam Alexander.

Area of expertise

1

Cancer

Global Leader

Medical University of South Carolina has run 106 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage III
2

Lung Cancer

Global Leader

Medical University of South Carolina has run 106 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
EGFR positive

Top PIs

Clinical Trials running at Medical University of South Carolina

Skin Cancer

Lung Cancer

Breast Cancer

Multiple Myeloma

Pancreatic Cancer

Breast cancer

Kidney Cancer

Bladder Cancer

Testicular cancer

Crohn's Disease

Image of trial facility.

Radiation + Immunotherapy

for Head and Neck Cancer

This phase III trial compares pembrolizumab with radiation therapy to pembrolizumab without radiation therapy (standard therapy) given after pembrolizumab plus chemotherapy for the treatment of patients with squamous cell carcinoma of the head and neck that has spread from where it first started (primary site) to other places in the body (metastatic). Pembrolizumab is a type of immunotherapy that stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells. Radiation therapy uses high-powered rays to kill cancer cells. Giving radiation with pembrolizumab may be more effective at treating patients with metastatic head and neck cancer than the standard therapy of giving pembrolizumab alone.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Cemiplimab + Surgery

for Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Cetuximab + Pembrolizumab

for Head and Neck Cancer

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.

Recruiting

2 awards

Phase 3

16 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Medical University of South Carolina?

Where is Medical University of South Carolina located?

Who should I call to ask about financial aid or insurance network?

What insurance does Medical University of South Carolina accept?

What awards or recognition has Medical University of South Carolina received?